Omeprazole Apteo Med

Omeprazole, the active ingredient in Omeprazole Apteo Med, is a proton pump inhibitor presented as an oral dosage form for oral use. It reduces gastric acid production and is employed in the management of acid‑related disorders such as gastroesophageal reflux disease, peptic ulcer disease, and Zollinger‑Ellison syndrome.

GNH USA supplies Omeprazole Apteo Med as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory compliance across markets.

Omeprazole is a proton pump inhibitor used to treat conditions caused by excess gastric acid.

- Gastroesophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing and prevents recurrence. - Helicobacter pylori eradication regimens: enhances the effectiveness of antibiotic therapy by suppressing acid. - Zollinger‑Ellison syndrome: controls hypersecretion of gastric acid associated with gastrin‑producing tumors.

Common side effects are generally mild and transient.

Common Side Effects: - Headache: mild to moderate pain often resolving without intervention. - Diarrhea: loose stools that may improve with continued therapy. - Abdominal pain: discomfort or cramping in the stomach area. - Nausea: feeling of sickness, sometimes accompanied by vomiting. - Flatulence: increased gas production. - Constipation: difficulty passing stools.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis presenting with watery diarrhea. - Severe allergic reactions: rash, swelling, or anaphylaxis requiring immediate medical attention. - Stevens‑Johnson syndrome: rare skin blistering and mucosal involvement. - Liver enzyme elevations: potential hepatotoxicity indicated by abnormal lab tests. - Hypomagnesemia: low magnesium levels with long‑term use, causing muscle cramps or arrhythmias. - Interstitial nephritis: inflammation of kidney tissue that may impair renal function.

Before initiating therapy, consider the following safety measures. - Assess renal function: adjust use in patients with severe impairment. - Monitor for infection: prolonged acid suppression can increase risk of C. difficile. - Check magnesium levels: long‑term therapy may cause deficiency. - Avoid abrupt discontinuation: may lead to rebound acid hypersecretion. - Pregnancy and lactation: use only if potential benefit outweighs risk. - Store at ambient temperature: keep in original container, protect from moisture and light.

Omeprazole may alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, increasing cardiovascular risk. - Atazanavir: decreased absorption, compromising antiviral efficacy. - High‑dose methotrexate: increased toxicity due to reduced clearance.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring more frequent monitoring. - Diazepam: elevated serum concentrations, may enhance sedation. - Digoxin: higher plasma levels, increasing risk of toxicity.